RayKnowChina Research Map
Shortlist0

RecruitingStomach cancerPhase not stated

Registered title, quoted from ClinicalTrials.gov

The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy

An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Peking University First Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorPeking University First Hospital北京大学第一医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07039474, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. ECOG performance status≤2.

    Inclusion criterion 4

  3. There exists at least one measurable target lesion according to the RECIST 1.1.

    Inclusion criterion 3

    18F-G1 PET/CT or 18F-FDG PET/CT is not performed in our department, or the interval between baseline imaging and immunotherapy is more than 30 days.

    Exclusion criterion 6

  4. Effective contraceptive measures will be adopted during the study period and within 6 months after the study.

    Inclusion criterion 6

    Women in the preconception period, pregnancy, or lactation period.

    Exclusion criterion 1

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07039474, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Subjects diagnosed with a malignant tumor by histopathology who are going to receive immunotherapy (monotherapy or combined immunotherapy) recommended by the multidisciplinary team.
  • Subjects didn't receive previous immunotherapy.
  • There exists at least one measurable target lesion according to the RECIST 1.1.
  • ECOG performance status≤2.
  • The expected survival time is ≥6 months.
  • Effective contraceptive measures will be adopted during the study period and within 6 months after the study.
  • Willing and able to fully understand and sign the informed consent form.

Exclusion Criteria:

  • Women in the preconception period, pregnancy, or lactation period.
  • Combined with other malignant tumor.
  • Diagnosed with autoimmune disease, or have long history of systemic steroid hormone therapy or immunosuppressive therapy.
  • Having a history of severe cardiovascular disease, severe hepatic and renal insufficiency.
  • Receiving radiotherapy or interventional therapy during the immunotherapy.
  • 18F-G1 PET/CT or 18F-FDG PET/CT is not performed in our department, or the interval between baseline imaging and immunotherapy is more than 30 days.

Quoted from ClinicalTrials.gov, NCT07039474, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07039474, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07039474